This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
AT LEAST 4 clinical trials on 3 continents are now under way to determine whether insulin-dependent diabetes mellitus (IDDM) can be prevented in highrisk patients by stimulating an immunoprotective response. The phase I trials involve the administration of insulin nasally or orally, reported researchers at the Juvenile Diabetes Foundation International's (JDFI) 4th World Conference on Diabetes Research, in Athens, Greece.
One of the trials, involving nasally administered insulin, was described by Leonard C. Harrison, MD, director of the Burnet Clinical Research Unit and professorial associate at the University of Melbourne School of Medicine, in Victoria, Australia. More than 30 children and young adults at high risk of developing the disease are enrolled in the double-blind, placebo-controlled, crossover trial in Australia. In the United States, the Diabetes Prevention Trial I, which involves orally administered insulin, is now under way, and there are at least 2 other ongoing trials in Europe and
Skolnick AA. First Type I Diabetes Prevention Trials. JAMA. 1997;277(14):1101-1102. doi:10.1001/jama.1997.03540380013003